CMN Weekly (13 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 13, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Editas Medicine
Main focus: Gene editing for the treatment of genetic diseases and cancer
Company stage: Clinical
Diseases: Sickle Cell Disease (SCD), Leber Congenital Amaurosis 10 (LCA10), Usher Syndrome 2a (USH2A), Autosomal Dominant Retinitis Pigmentosa 4 (RP4) , β-Thalassemia.
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:EDIT)
Location: Cambridge, MA, USA
Website: https://www.editasmedicine.com/
Pipeline: https://www.editasmedicine.com/gene-editing-pipeline/
Partners: Bluerock Therapeutics, Gamida Cell, Bristol Myers Squibb, Askbio, Sandhill Therapeutics
Editas Medicine is a US-based public gene therapy company. Editas has advanced two drugs into early stage clinical trials focusing on ocular disease and sickle cell disease, and the company also has several ongoing pre-clinical programmes. All of the company's trials are focused on two gene-editing technologies, CRISPR-Cas9 and CRISPR-Cas12a.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, and Transfusion Dependent Beta-Thalassemia, TDT, (NCT06363760)
Sponsors:
Editas Medicine, Inc.
Sponsors:
Editas Medicine, Inc.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
